Kaleida Health Acute Care Hospital (Medicare Certified) Location: 100 High Street, Buffalo, New York 14210 Ratings: Phone: (716) 859-8620 |
Sisters Of Charity Hospital Acute Care Hospital (Medicare Certified) Location: 2157 Main Street, Buffalo, New York 14214 Ratings: Phone: (716) 862-1000 |
Erie County Medical Center Acute Care Hospital (Medicare Certified) Location: 462 Grider Street, Buffalo, New York 14215 Ratings: Phone: (716) 898-3936 |
Mercy Hospital Of Buffalo Acute Care Hospital (Medicare Certified) Location: 565 Abbott Road, Buffalo, New York 14220 Ratings: Phone: (716) 826-7000 |
Brylin Hosp Psychiatric Hospital (Medicare Certified) Location: 1263 Delaware Ave, Buffalo, New York 14209 Ratings:NA Phone: (716) 886-8200 |
Buffalo Psychiatric Center Psychiatric Hospital (Medicare Certified) Location: 400 Forest Ave, Buffalo, New York 14213 Ratings:NA Phone: (716) 885-2261 |
News Archive
Details of a new method to detect diabetic neuropathy in patients in less than five minutes using their sweat glands was presented today at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress in Phoenix, Arizona by Aaron I. Vinik, M.D., Ph.D., F.C.P., M.A.C.P., F.A.C.E., Professor of Medicine and Director of Research and the Neuroendocrine Unit at Eastern Virginia Medical School.
Dr Rachel Huxley, lead author of the paper and Acting Director of Nutrition and Lifestyle at The George Institute said, "Although there was support for a small association between birth weight and an individual's future risk of heart disease, the relationship is not as strong as earlier studies have suggested.
With "scores of commercial serology tests for tuberculosis ... being sold in high-burden countries," the "WHO is due to release a negative policy recommendation - the first of its kind for the organisation" - after several reviews have "indicated poor performance of these tests," Lancet World Report writes in a piece that documents the health risks associated with a growing number of inaccurate TB tests.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 1 days ago